title: Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.
abstract: The Step study of a recombinant adenovirus serotype 5 (Ad5)-based human immunodeficiency virus type 1 (HIV-1) vaccine revealed an increased risk of HIV-1 acquisition in vaccinees who were Ad5 seropositive at baseline. We therefore investigated whether preexisting Ad seropositivity to 7 different Ad serotypes was associated with increased risk of HIV-1 infection in 3 HIV-1 vaccine efficacy trials. In a case-control study involving 1570 adults enrolled in the VAX003 and VAX004 trials of a recombinant protein subunit HIV-1 vaccine and in the Step study, we observed that preexisting seropositivity to multiple Ad serotypes was not intrinsically associated with increased risk of HIV-1 acquisition.
authors.affiliation: Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Stephenson
authors.forename: John
authors.initials: J
authors.lastname: Hural
authors.forename: Susan P
authors.initials: SP
authors.lastname: Buchbinder
authors.forename: Faruk
authors.initials: F
authors.lastname: Sinangil
authors.forename: Dan H
authors.initials: DH
authors.lastname: Barouch
mesh_terms: D000258:Adenovirus Infections, Human / Q000150:complications* / Q000276:immunology*; D000260:Adenoviruses, Human / Q000276:immunology*; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D005260:Female; D015658:HIV Infections / Q000453:epidemiology* / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D008297:Male
chemical_list: D000914:Antibodies, Viral